表紙
市場調査レポート

胸腺がん:パイプライン製品の分析

Thymus Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 213054
出版日 ページ情報 英文 109 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
胸腺がん:パイプライン製品の分析 Thymus Cancer - Pipeline Review, H1 2016
出版日: 2016年04月30日 ページ情報: 英文 109 Pages
概要

胸腺がんは、胸腺で発症するまれながんです。症状は、息切れ、咳、胸痛、嚥下困難、食欲不振、頭痛、体重減少などが見られます。素因として、年齢やその他の自己免疫疾患(重症筋無力症、赤芽球癆、低ガンマグロブリン血症など)が挙げられます。

当レポートでは、胸腺がんに対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

胸腺がんの概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Merck & Co., Inc.
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG
  • Onxeo SA
  • 大日本住友製薬

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • amrubicin hydrochloride
  • belinostat
  • buparlisib hydrochloride
  • Cell Therapy 1 for Oncology
  • milciclib
  • MK-2206 + selumetinib sulfate

パイプライン製品の最新動向

製品開発のマイルストーン

  • 注目のニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8063IDB

Summary

Global Markets Direct's, 'Thymus Cancer - Pipeline Review, H1 2016', provides an overview of the Thymus Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thymus Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thymus Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Thymus Cancer
  • The report reviews pipeline therapeutics for Thymus Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Thymus Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Thymus Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Thymus Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Thymus Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Thymus Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thymus Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Thymus Cancer - Overview
  • Thymus Cancer - Therapeutics under Development by Companies
  • Thymus Cancer - Pipeline Products Glance
    • Clinical Stage Products
  • Thymus Cancer - Products under Development by Companies
  • Thymus Cancer - Companies Involved in Therapeutics Development
    • Cellceutix Corporation
    • Merck & Co., Inc.
    • Novartis AG
    • Onxeo SA
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Taiwan Liposome Company, Ltd.
    • Tiziana Life Sciences Plc
  • Thymus Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • amrubicin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • belinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buparlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KM-3174 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • milciclib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MK-2206 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MK-2206 + selumetinib sulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pasireotide ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TLC-388 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Thymus Cancer - Recent Pipeline Updates
  • Thymus Cancer - Dormant Projects
  • Thymus Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Aug 11, 2015: Cellceutixs Kevetrin and Thymoma - a Rare Cancer
      • Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014
      • May 14, 2014: Phase II data of Nerviano Medical Science's kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO
      • Jul 18, 2013: Belinostat gets European orphan drug designation for the treatment of malignant thymomas
      • May 17, 2012: Topotarget Presents Phase I/II Clinical Data Of Belinostat At ASCO 2012
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Thymus Cancer, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Thymus Cancer - Pipeline by Cellceutix Corporation, H1 2016
  • Thymus Cancer - Pipeline by Merck & Co., Inc., H1 2016
  • Thymus Cancer - Pipeline by Novartis AG, H1 2016
  • Thymus Cancer - Pipeline by Onxeo SA, H1 2016
  • Thymus Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Thymus Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016
  • Thymus Cancer - Pipeline by Tiziana Life Sciences Plc, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Thymus Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Thymus Cancer - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Thymus Cancer, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top